% yoy. EBITDA margin rose from 26% of hospital revenue in 3Q18 to 28% in 3Q19. The promising EBITDA was attributable to not only the revenue growth but also the effective cost control as mentioned above
cost. EBITDA in 3Q22 was Bt22,091mn dropped -3.5%YoY mostly from resumed marketing spending and surging network OPEX due to higher utility price and network expansion. It dropped -1.2% QoQ due to core
cost. EBITDA in 3Q22 was Bt22,091mn dropped -3.5%YoY mostly from resumed marketing spending and surging network OPEX due to higher utility price and network expansion. It dropped -1.2% QoQ due to core
cost. EBITDA in 3Q22 was Bt22,091mn dropped -3.5%YoY mostly from resumed marketing spending and surging network OPEX due to higher utility price and network expansion. It dropped -1.2% QoQ due to core
to 72% in 2Q18. The improved margin was not only attributed by the increase of fixed income from SW revenue and higher revenue per visit of non-SW category but also from the efficient cost control of
. Spending was boosted by the government’s stimulus measures and the export sector was supported by brightening global economic prospects. However, any potential Thai economic recovery over the rest of the
Control | - |- Compliance / Internal control | - |- Information Technology |- Internal operation of Securities Companies | - |- Outsourcing Services | - |- Appoint service provider OR marketing
outbreak control measures are being gradually relaxed and Vaccination is more progressive. 2). The effect of outstanding demand from the previous period and 3). Government measures that continue to bolster
outbreak control measures are being gradually relaxed and Vaccination is more progressive. 2). The effect of outstanding demand from the previous period and 3). Government measures that continue to bolster
, decreasing of 128 million baht or 2% q-q and 12% y-y. This is the result of the COVID-19 pandemic situation and economic slowdown has made consumers more cautious on spending, especially in cash loan products